Weight Watchers Broadens GLP-1 Reach As Eli Lilly Pursues New Kidney Disease Therapies - Eli Lilly (NYSE:

Weight Watchers joins LillyDirect for GLP-1 access as Eli Lilly signs a kidney disease research pact with Ascidian worth up to $1.9 billion.

Raccontata dabenzinga.com